Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Parma – page 17

219 clinical trials in Parma, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Parma at a glance
219
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

219 trials in Parma

Open in trial search

HER2 mutant non-small cell lung cancer

Not recruiting

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Marginal zone lymphoma

Not recruiting

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Pentixapharm AG

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab Vedotin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer stage IV+1

Not recruiting

Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986315
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Factor VIII deficiency

Not recruiting

Study on Physical Activity and Joint Health in Patients Aged 12 and Older with Severe Hemophilia A Treated with Efanesoctocog Alfa for 24 Months

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Congenital generalised lipodystrophy

Not recruiting

Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Metreleptin
  • Sponsor:Amryt Pharmaceuticals Designated Activity Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Parma

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and breast cancer treatments. Investigations include innovative immunotherapy approaches and targeted therapies for various cancer types.

  • Novel therapies for NSCLC patients
  • Triple-negative breast cancer treatments
  • Multiple myeloma management strategies

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Respiratory Medicine

Studies examining treatments for respiratory syncytial virus (RSV) infections in high-risk populations. Advanced research into preventive therapies and management strategies.

  • RSV prevention in infants
  • Respiratory support strategies
  • Critical care ventilation protocols

Focus on developing protective measures for vulnerable patient populations.

03 Transplant Medicine

Clinical trials evaluating new approaches to kidney transplantation and prevention of complications. Research on reducing delayed graft function and improving transplant outcomes.

  • Post-transplant care optimization
  • Graft function improvement
  • Novel immunosuppressive strategies

Emphasis on enhancing long-term transplant success rates.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.